|
|
2
|
|
Financial Highlights |
|
|
3
|
|
News in 2003 |
Letter from Daniel Vasella
|
5
|
|
The New Number Five in Pharmaceuticals |
|
Division and Business Units
|
9
|
|
Pharmaceuticals
Giving Thalassemia Patients a Choice
Discovering Pharmaceuticals Reliably and Predictably
The Long Road to Blood-Pressure Control
Treating Breast Cancer Will Never Be the Same
Epilepsy - Putting Children First
A New Frontier in the Fight Against Severe Allergic Asthma
Two Decades of Leadership in Transplantation
Hearing the Patient, Healing the Patient - Irritable Bowel Syndrome
The Right Note: Saving a Singer’s Sight |
|
|
32
|
|
Consumer Health
Sandoz - Building a World Leader in Generics
OTC - The Value of Global Brands
Animal Health - Up and Running, Despite Arthritis
Medical Nutrition - A New Relevance for Cancer Patients
Infant & Baby - Alerting Parents to the Dangers of Childhood Obesity
CIBA Vision - Innovation in Focus |
|
Corporate Citizenship
|
45
|
|
Active Societal Engagement |
|
Health, Safety and Environment
|
57
|
|
Turning Strong Commitment Into Firm
Actions |
|
Human Resources
|
69
|
|
Fulfilling Career Aims |
|
Corporate Governance Section
|
77
|
|
Corporate Governance |
|
|
90
|
|
Board of Directors |
|
|
94
|
|
Executive Committee |
|
|
96
|
|
Business Unit Heads |
|
|
99
|
|
Operating and Financial Review |
|
|
111
|
|
Equity Strategy and Share Information |
|
|
118
|
|
Group Consolidated Financial Statements
and Notes |
|
|
152
|
|
Principal Companies |
|
|
154
|
|
Reconciliation to US GAAP |
|
|
|
|
Financial Statements of Novartis
AG |
|
Due Dates for Reporting in 2004
|
172
|
|
|
|
Contacts
|
173
|
|
|
1